PATH swells in size

Xconomy outlines the rapid growth of Seattle-based PATH, which has used millions in grants from the Gates Foundation to pursue research into new vaccines. Since 2000, PATH has grown from 240 employees to a staff of 775 and its annual budget has hit $240 million. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.